Skip to content
10-K

Annual Report

VYNE THERAPEUTICS INC. VYNE

0001566044-26-000002

← back to feed
Filed
Feb 27, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 12, 2026 33.32M sh
Shares Diluted FY 2025 · Dec 31, 2025 42.77M sh
Shares Diluted FY 2025 · Dec 31, 2024 42.59M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$33.12M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$33.97M
Short Term Investments FY 2025 · Dec 31, 2025 $4.98M
Short Term Investments FY 2025 · Dec 31, 2024 $41.59M
Cash And Equivalents FY 2025 · Dec 31, 2025 $24.03M
Cash And Equivalents FY 2025 · Dec 31, 2024 $19.93M
Stockholders Equity FY 2025 · Dec 31, 2025 $27.77M
Stockholders Equity FY 2025 · Dec 31, 2024 $52.09M
Stockholders Equity FY 2025 · Dec 31, 2023 $88.74M
Current Liabilities FY 2025 · Dec 31, 2025 $2.4M
Current Liabilities FY 2025 · Dec 31, 2024 $14.82M
Total Liabilities FY 2025 · Dec 31, 2025 $2.4M
Total Liabilities FY 2025 · Dec 31, 2024 $14.82M
Current Assets FY 2025 · Dec 31, 2025 $30.01M
Current Assets FY 2025 · Dec 31, 2024 $64.44M
Total Assets FY 2025 · Dec 31, 2025 $30.16M
Total Assets FY 2025 · Dec 31, 2024 $66.91M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.62
Eps Diluted FY 2025 · Dec 31, 2024 −$0.93
Eps Basic FY 2025 · Dec 31, 2025 −$0.62
Eps Basic FY 2025 · Dec 31, 2024 −$0.93
Rd Expense FY 2025 · Dec 31, 2025 $19.24M
Rd Expense FY 2025 · Dec 31, 2024 $30.95M
Net Income FY 2025 · Dec 31, 2025 −$26.48M
Net Income FY 2025 · Dec 31, 2024 −$39.83M
Operating Income FY 2025 · Dec 31, 2025 −$29.75M
Operating Income FY 2025 · Dec 31, 2024 −$43.64M
Revenue FY 2025 · Dec 31, 2025 $570K
Revenue FY 2025 · Dec 31, 2024 $501K